Cargando…
Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives
Respiratorytract infections (RTIs) are frequent and life-threatening diseases, accounting for several millions of deaths worldwide. RTIs implicate microorganisms, including viruses (influenza virus, coronavirus, respiratory syncytial virus (RSV)), bacteria (Pseudomonas aeruginosa, Streptococcus pneu...
Autores principales: | Mayor, Alexie, Chesnay, Adélaïde, Desoubeaux, Guillaume, Ternant, David, Heuzé-Vourc’h, Nathalie, Sécher, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917879/ https://www.ncbi.nlm.nih.gov/pubmed/33668613 http://dx.doi.org/10.3390/vaccines9020151 |
Ejemplares similares
-
Inhalation of Immuno-Therapeutics/-Prophylactics to Fight Respiratory Tract Infections: An Appropriate Drug at the Right Place!
por: Sécher, Thomas, et al.
Publicado: (2019) -
Pneumocystis Pneumonia: Pitfalls and Hindrances to Establishing a Reliable Animal Model
por: Chesnay, Adélaïde, et al.
Publicado: (2022) -
Alternative Routes of Administration for Therapeutic Antibodies—State of the Art
por: Pitiot, Aubin, et al.
Publicado: (2022) -
Inhaled antibodies: formulations require specific development to overcome instability due to nebulization
por: Mayor, Alexie, et al.
Publicado: (2021) -
Targeting Aspergillus fumigatus Crf Transglycosylases With Neutralizing Antibody Is Relevant but Not Sufficient to Erase Fungal Burden in a Neutropenic Rat Model
por: Chauvin, David, et al.
Publicado: (2019)